Market Mover: Cogent (COGT) Climbs at Midday August 5

Equities Staff  |

Cogent Biosciences Inc (NASDAQ: COGT) shares have risen 13.05%, or $1.39 per share, as on 11:51:35 est today. Since opening at $11.58, 383,420 shares of Cogent have exchanged hands and the stock has ranged between $12.14 and $11.50.  

Already the company has a YTD change of 39.74%.

Cogent expects its next earnings on 2022-08-15.

For technical charts, analysis, and more on Cogent visit the company profile.

About Cogent Biosciences Inc

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent Biosciences is headquartered in Cambridge, MA.

To get more information on Cogent Biosciences Inc and to follow the company's latest updates, you can visit the company's profile page here: Cogent Biosciences Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content